These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25075187)

  • 1. Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways.
    Chen J; Shao R; Li L; Xu ZP; Gu W
    Int J Nanomedicine; 2014; 9():3403-11. PubMed ID: 25075187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergistic anti-proliferative effect of the combination of diosmin and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line occurs through inhibition of the PI3K/Akt/mTOR/NF-κB axis.
    Helmy MW; Ghoneim AI; Katary MA; Elmahdy RK
    Mol Biol Rep; 2020 Mar; 47(3):2217-2230. PubMed ID: 32088816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer.
    Jin N; Jiang T; Rosen DM; Nelkin BD; Ball DW
    Clin Cancer Res; 2011 Oct; 17(20):6482-9. PubMed ID: 21831957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic inhibition of colon cancer cell growth with nanoemulsion-loaded paclitaxel and PI3K/mTOR dual inhibitor BEZ235 through apoptosis.
    Zou H; Li L; Garcia Carcedo I; Xu ZP; Monteiro M; Gu W
    Int J Nanomedicine; 2016; 11():1947-58. PubMed ID: 27226714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity.
    Durrant DE; Das A; Dyer S; Tavallai S; Dent P; Kukreja RC
    Mol Pharmacol; 2015 Sep; 88(3):512-23. PubMed ID: 26101222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of sonic hedgehog and PI3K/Akt/mTOR pathways cooperate in suppressing survival, self-renewal and tumorigenic potential of glioblastoma-initiating cells.
    Nanta R; Shrivastava A; Sharma J; Shankar S; Srivastava RK
    Mol Cell Biochem; 2019 Apr; 454(1-2):11-23. PubMed ID: 30251117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
    Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
    Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
    Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
    Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curcumin significantly enhances dual PI3K/Akt and mTOR inhibitor NVP-BEZ235-induced apoptosis in human renal carcinoma Caki cells through down-regulation of p53-dependent Bcl-2 expression and inhibition of Mcl-1 protein stability.
    Seo BR; Min KJ; Cho IJ; Kim SC; Kwon TK
    PLoS One; 2014; 9(4):e95588. PubMed ID: 24743574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
    Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines.
    Durrant DE; Das A; Dyer S; Kukreja RC
    Biochim Biophys Acta Gen Subj; 2020 Jun; 1864(6):129556. PubMed ID: 32061787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y; Di W; Yang Q; Lu Z; Cai W; Wu J
    Clin Lab; 2015; 61(8):1043-51. PubMed ID: 26427150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
    Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells.
    Chen J; Shao R; Li F; Monteiro M; Liu JP; Xu ZP; Gu W
    Clin Exp Pharmacol Physiol; 2015 Dec; 42(12):1317-26. PubMed ID: 26399781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
    Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
    Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W; Liu X; Zhang Y; Li A; Xie Y; Zhou S; Song L; Xu R; Ma Y; Cai S; Tang X
    Biomed Res Int; 2021; 2021():5556306. PubMed ID: 33987439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
    Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
    Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
    Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
    Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.